New research provides evidence that an old drug may provide relief for people with advanced Parkinson’s, according to a study released today that will be presented at the American Academy of Neurology’s 69th Annual Meeting in Boston, April 22 to 28, 2017.
Small trial uses chloroquine to nix the process of "autophagy" that some cancer cells use to resist treatment, resensitzing glioblastoma to targeted therapy
Researchers have developed a capsule that, when dissolved in the stomach, releases a star-shaped material containing drugs that help to prevent malaria infections and lasts for up to two weeks.
Transcription factors, the tiny proteins that switch genes on or off in the nucleus of cells, are considered unreachable molecular targets for drugs attempting to treat medical conditions. Overcoming this challenge, researchers discovered a small molecular compound that successfully blocks a transcription factor and its pro-inflammatory and hyper-mucous activity in asthma. In a study published online April 18 by Science Signaling, scientists test a new compound they call RCM-1.
UCLA scientists have unlocked an important mechanism that allows chemotherapy-carrying nanoparticles—extremely small objects between 1 and 100 nanometers (a billionth of a meter)—to directly access pancreatic cancer tumors, thereby improving the ability to kill cancer cells and hence leading to more effective treatment outcome of the disease. The researchers also confirmed the key role of a peptide (an extremely small protein) in regulating vascular access of the nanoparticle to the cancer site.
According to the National Cancer Institute, nearly one-third of cancer deaths can be attributed to a wasting syndrome known as cachexia. Cachexia, an indicator of the advanced stages of disease, is a debilitating disorder that causes loss of appetite, lean body mass and can lead to multi-organ failure. Now, researchers at the University of Missouri in partnership with Tensive Controls, Inc. have developed a drug that could reverse cachexia. The team currently is seeking canine candidates for a pilot study to test the new drug.
Chemists at The Scripps Research Institute (TSRI) have developed a broad and strikingly easy method for synthesizing a class of molecules that have demonstrated value as pharmaceuticals.
Medication for addiction treatment (MAT) with buprenorphine or methadone is an appropriate and accepted treatment for pregnant women with opioid use disorder (OUD), according to a research review and update in the Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine (ASAM). The journal is published by Wolters Kluwer.
Vanderbilt geneticists have developed an effective method for identifying the plant genes that produce the chemical ammunition plants use to protect themselves from predation and is a natural source of many important drugs.
People taking corticosteroids for short-term relief were more likely to break a bone, have a potentially dangerous blood clot or suffer a life-threatening bout of sepsis in the months after their treatment, compared with similar adults who didn’t use the drugs, a new study finds.
Cancer expert Antonio Giordano, MD, PhD, Director of the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University, describes the recent progress and future possibilities of treating SCLC.
A team of engineers from Washington University in St. Louis has combined nanoparticles, aerosol science and locusts in new proof-of-concept research that could someday vastly improve drug delivery to the brain, making it as simple as a sniff.
Ryan’s Quest, Michael’s Cause and Pietro’s Fight are non-profits founded by families of boys with Duchenne muscular dystrophy who believe that their global collaboration is paramount to see potential therapies through the drug pipeline.
Researchers published in Nature Medicine from the George Washington University, the University of Perugia, and the University of Rome have discovered a potential new drug to treat and stop the progression of cystic fibrosis. Thymosin α1 is a novel therapeutic single molecule-based therapy that not only corrects genetic and tissue defects, but also significantly reduces inflammation seen in cystic fibrosis patients.
A new study published in Nature provides clues that could enhance physicians’ ability to pinpoint, in real-time, which patients are not responding to therapy – and intervene with additional drugs to boost the chances of shrinking tumors.
Rutgers University scientists have determined the three-dimensional structure of the target of the first-line anti-tuberculosis drug rifampin. They have also discovered a new class of potential anti-tuberculosis drugs that kill rifampin-resistant and multi-drug-resistant tuberculosis bacteria. Tuberculosis (TB) bacteria infect a third of the world's population and the disease kills 1.8 million people annually.
Spanish multinational veterinary pharmaceutical company HIPRA will establish its North American headquarters at the South Jersey Technology Park at Rowan University in Mantua Township, New Jersey.
Many hypertension medications currently on the market target the AT1 receptor because of its well-understood role in blood pressure regulation; they block AT1 in order to reduce blood pressure. The AT2 receptor, on the other hand, is still an elusive drug target despite multiple studies of its function. Now, researchers have solved its structure to hone in on its function. The results of the experiments were surprising in several ways. First, although both compounds were designed to block and deactivate the receptors, they left AT2 in a state that appeared to be active. In addition, although AT1 and AT2 were thought to be very similar, the pockets where the receptors bind to the compounds exhibited marked differences.
As a primary point of contact for patients receiving anesthesia, procedural sedation, and pain management services, Certified Registered Nurse Anesthetists (CRNAs) are answering the Surgeon General’s call to end the opioid crisis with a more holistic approach to pain management designed to reduce dependence on prescription medications and offering patients greater transparency, understanding and engagement in their own care.
Researchers led by Julian E. Stelzer, PhD, associate professor in the department of physiology and biophysics at Case Western Reserve University School of Medicine, have found a new target for drug developers seeking straightforward ways to improve cardiac output in heart failure patients.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right